| 120.27 3.17 (2.71%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 152.1 | 1-year : | 177.66 |
| Resists | First : | 130.22 | Second : | 152.1 |
| Pivot price | 114.15 |
|||
| Supports | First : | 113.46 |
Second : | 103.11 |
| MAs | MA(5) : | 114.89 |
MA(20) : | 115.91  |
| MA(100) : | 102.05 |
MA(250) : | 98.03 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 50.5 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 130.69 | Low : | 73.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GKOS ] has closed below upper band by 16.5%. Bollinger Bands are 11.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 120.91 - 121.5 | 121.5 - 122 |
| Low: | 114.92 - 115.59 | 115.59 - 116.16 |
| Close: | 119.25 - 120.31 | 120.31 - 121.22 |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Sat, 21 Feb 2026
Glaukos (NYSE:GKOS) Cut to "Hold" at Wall Street Zen - MarketBeat
Thu, 19 Feb 2026
Glaukos Stock Jumps 13% After Q4 Beat: Here’s What Its 2026 Guidance Signals - TIKR.com
Wed, 18 Feb 2026
Stifel reiterates Glaukos stock rating on product momentum - Investing.com
Wed, 18 Feb 2026
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook - Nasdaq
Wed, 18 Feb 2026
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript - Insider Monkey
Wed, 18 Feb 2026
Glaukos Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 57 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 101.6 (%) |
| Shares Short | 2,230 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -1.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.4 |
| Profit Margin | -18.7 % |
| Operating Margin | -12.3 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -12.2 % |
| Qtrly Rev. Growth | 38 % |
| Gross Profit (p.s.) | 6.28 |
| Sales Per Share | 8.18 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -78.1 |
| PEG Ratio | 0 |
| Price to Book value | 8.96 |
| Price to Sales | 14.7 |
| Price to Cash Flow | -327.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|